Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis.
Mastrantoni L, Chiaravalli M, Spring A, Beccia V, Di Bello A, Bagalà C, Bensi M, Barone D, Trovato G, Caira G, Giordano G, Bria E, Tortora G, Salvatore L. Mastrantoni L, et al. Lancet Oncol. 2024 Nov 11:S1470-2045(24)00511-4. doi: 10.1016/S1470-2045(24)00511-4. Online ahead of print. Lancet Oncol. 2024. PMID: 39542008
Impact of Comprehensive Genome Profiling on the Management of Advanced Non-Small Cell Lung Cancer: Preliminary Results From the Lung Cancer Cohort of the FPG500 Program.
Vitale A, Mastrantoni L, Russo J, Giacomini F, Giannarelli D, Duranti S, Vita E, Nero C, D'Argento E, Pasciuto T, Giacò L, Di Salvatore M, Panfili A, Stefani A, Cancellieri A, Lococo F, De Paolis E, Livi V, Daniele G, Trisolini R, Minucci A, Margaritora S, Lorusso D, Normanno N, Scambia G, Tortora G, Bria E. Vitale A, et al. Among authors: mastrantoni l. JCO Precis Oncol. 2024 Oct;8:e2400297. doi: 10.1200/PO.24.00297. Epub 2024 Oct 7. JCO Precis Oncol. 2024. PMID: 39374480
The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis.
Mastrantoni L, Giordano G, Vita E, Horn G, Russo J, Orlandi A, Daniele G, Giannarelli D, Tortora G, Bria E. Mastrantoni L, et al. Cancer Treat Res Commun. 2024 Sep 6;41:100842. doi: 10.1016/j.ctarc.2024.100842. Online ahead of print. Cancer Treat Res Commun. 2024. PMID: 39260066 Free article. Review.
To explain the unexplainable in MONARCH 3 overall survival: the restricted mean survival time. Letter to the Editor regarding 'Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3' by M. P. Goetz et al.
Orlandi A, Mastrantoni L, Bria E, Tortora G. Orlandi A, et al. Among authors: mastrantoni l. Ann Oncol. 2024 Aug;35(8):748-749. doi: 10.1016/j.annonc.2024.05.544. Epub 2024 Jun 3. Ann Oncol. 2024. PMID: 38838845 No abstract available.
Symptomatic androgen deficiency and sexual dysfunctions in male patients receiving alectinib for ALK-positive advanced non-small cell lung cancer.
Vita E, Monaca F, Milardi D, Mastrantoni L, Stefani A, Vergani E, Russo J, Barone D, Sparagna I, Vitale A, Scala A, Occhipinti D, Di Salvatore M, Pontecorvi A, Tortora G, Bria E. Vita E, et al. Among authors: mastrantoni l. Cancer. 2024 Aug 1;130(15):2611-2620. doi: 10.1002/cncr.35293. Epub 2024 Mar 28. Cancer. 2024. PMID: 38549441
Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC).
Vita E, Stefani A, Piro G, Mastrantoni L, Cintoni M, Cicchetti G, Sparagna I, Monaca F, Horn G, Russo J, Barone D, Di Salvatore M, Trisolini R, Lococo F, Mazzarella C, Cancellieri A, Carbone C, Larici AR, Mele MC, Pilotto S, Milella M, Tortora G, Bria E. Vita E, et al. Among authors: mastrantoni l. Cancer Immunol Immunother. 2023 Nov;72(11):3803-3812. doi: 10.1007/s00262-023-03533-0. Epub 2023 Sep 5. Cancer Immunol Immunother. 2023. PMID: 37668709 Free PMC article.
Adjuvant denosumab in early breast cancer: a systematic review and meta-analysis of randomized controlled clinical trials.
Mastrantoni L, Garufi G, Di Monte E, Maliziola N, Pasqualoni M, Pontolillo L, Pannunzio S, Cannizzaro MC, Di Bello A, Fabi A, Palazzo A, Tortora G, Bria E, Orlandi A. Mastrantoni L, et al. Ther Adv Med Oncol. 2023 May 29;15:17588359231173180. doi: 10.1177/17588359231173180. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 37284523 Free PMC article.
13 results